Yüklüyor......
Targeting β-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins
Progressive insulin secretory defects, due to either functional abnormalities of the pancreatic β-cells or a reduction in β-cell mass, are the cornerstone of type 2 diabetes. Incretin-based drugs hold the potential to improve glucose tolerance by immediate favorable effect on β-cell physiology as we...
Kaydedildi:
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
The Endocrine Society
2008
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2528856/ https://ncbi.nlm.nih.gov/pubmed/18292465 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/er.2007-0031 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|